England’s chief medical officer professor Dame Sally Davies has highlighted the need for routine access to genetic testing to improve diagnosis and treatment of cancer in the UK.
Go deeper with GlobalData
Davies urged the clinicians and the government to jointly work towards greater use of new genetic techniques to ensure increased cancer survival rates.
The ability of the genetic testing to precisely detect the faults in DNA is expected to facilitate faster diagnosis and determination of targeted treatments.
Davies said: “This technology has the potential to change medicine forever but we need all NHS staff, patients and the public to recognise and embrace its huge potential.”
See Also:
A report published by the professor called for training of current and future clinicians, alongside better access to genomic tests within five years.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe report further urged investment in research and services to allow equal patient access, as well as prioritisation of research and international collaboration.
The initiative could potentially have to overcome potential challenges such as data protection, clinician attitudes and the public, Davies noted.
According to Cancer Research UK, companies have started altering the design of their clinical trials to allow precise treatments.
Cancer Research UK chief executive Harpal Kumar said: “This timely report from the chief medical officer showcases just how much is now possible in genomics research and care within the NHS.
“Cancer Research UK is determined to streamline research, to find the right clinical trial for cancer patients and to ensure laboratory discoveries benefit patients.”
The organisation has collaborated with AstraZeneca and Pfizer to conduct the National Lung Matrix Trial, in which patients are assigned to select treatment based on their cancer’s genetic makeup.
Image: Genetic testing can pinpoint the faults in DNA that have led to cancer forming. Photo: courtesy of Cancer Research UK.
